Circle is developing a new paradigm for macrocycle drug discovery for cell-permeable molecules that can be delivered by oral administration. Circle’s macrocycle development platform is initially focusing its development efforts on intracellular protein-protein interactions that are key drivers in cancer. Its lead program targets cyclins A and E, which are part of the regulatory machinery that controls the progression of cells through the cell growth and division cycle.